Introduction
The large family of Ets transcription factors primarily control a spectrum of developmental processes in animals ranging from primitive metazoans to mammals (Graves and Petersen, 1998; Laudet et al., 1999; Papas et al., 1997; Remy and Baltzinger, 2000) . At present, nearly 30 mammalian family members have been isolated. Ets signal transduction is implicated in hematopoiesis and vasculogenesis/angiogenesis at the earliest stages of embryogenesis and is later involved in tissue development. In adult animals, Ets genes are expressed in a variety of tissues including hematopoietic tissue, vasculature, brain and central nervous system, mammary gland, endometrium, ovaries, testes, kidneys and lungs.
This review concentrates on the expression pattern and relationship among the Ets family of transcription factors in mammalian development. The role of Ets in mammalian development has been studied in lymphoid tissues (Ets1, Ets2, Erg, Fli1, TEL1, PU.1, SpiB and Elf), brain (Ets1, Ets2, Fli1, TEL1 and PEA3), bone (Ets1, Ets2, PEA3, Erg and PU.1) and mammary gland (Ets1, Ets 2 and PEA3) and in cell and tissue development (Table 1) . Ets genes have diverse functions, including the regulation of cell proliferation, dierentiation, migration, apoptosis and mesenchymalepithelial interactions. A complementary review on Etsgenes in amphibian and avian development is provided by Remy and Baltzinger in this issue.
An overview of the expression patterns of Ets family members in the embryo and adult
High levels of Ets1 initially appear in the blood islands of the yolk sac where hemangioblasts, the common precursors of hematopoietic and vascular lineages, are located (Pardanaud and Dieterlen-Lievre, 1993; Vandenbunder et al., 1989) . Areas expressing Ets1 prior to morphogenesis include the region of neural crest formation, the developing nervous system (the anterior neuroplate and the closed neural tube) and vascular structures (the perioptic vascular plexus posterior to the developing optic vesicles) ( Table 1) . During mid-gestation, expression of Ets1 in the vascular network extends to the developing heart, dorsal aorta and intersegmental arteries. Ets1 expression is also found in the choroid plexus, the cells surrounding neuronal tissue within the vascular and supporting layers of the meninges, and the developing capillary structures within the central nervous system (in which expression continues until the central nervous system reaches maturity). During morphogenesis, Ets1 expression occurs in non-lymphoid tissues, including the gut, lungs, kidneys and skin, and lymphoid tissues, including the spleen and cortical and medullary areas of the thymus (Maroulakou et al., 1994) .
During the ®rst week of the neonatal period, Ets1 levels of expression are high in the cortical and medullary regions of the thymus and in the follicles and white pulp of the spleen, increasing as the spleen matures. High level Ets1 expression is maintained in a restricted subset of adult tissues, including the spleen, thymus, non-lymphoid tissues of the lungs, gut, mesenchyme (Maroulakou et al., 1994) , and mammary glands (Delannoy-Courdent et al., 1996) . In human tissue, Ets1 is also expressed in the endometrium (Kilpatrick et al., 1999) , ovaries (Rowe and Propst, 1992) , and in astrocytes of the nervous system (Amouyel et al., 1988) . Expression occurs in adult endothelial cells during wound healing, tumor angiogenesis, and re-endothelialization after denuding injury (Bolon et al., 1995; Calmels et al., 1995; Wernert et al., 1992 Wernert et al., , 1994 .
The hallmarks of Ets2 are its high level and ubiquitous pattern of expression throughout embryonic and neonatal development. Initially, embryonic expression of Ets2 occurs at high levels in the Oncogene (2000) 19, 6432 ± 6442 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: IG Maroulakou trophectoderm (Yamamoto et al., 1998) , a layer of extra-embryonic ectoderm formed in the pre-implantation embryo. During development of the nervous system, Ets2 expression is initially detected in the neural pore and subsequently extends from the medulla oblongata through the length of the posterior region of the developing spinal cord (Table 1) . At mid-gestation, Ets2 expression is detected in the epithelial layers of the kidneys, lungs, gut and uterus. High level expression of Ets2 is associated with the ®rst appearance of cartilage and bone primordia. Ets2 expression markedly decreases after bone-formation. In addition, high level Ets2 expression is detected in lymphoid tissues and is restricted to the cortical region of the thymus. This expression pattern continues throughout adult life (Maroulakou et al., 1994) .
In the adult mouse, expression of Ets2 is primarily restricted to speci®c regions of the brain, such as the dentate gyrus, the CA1, CA2 and CA3 areas of the hippocampus, and the granule layer of the cerebellum (Maroulakou et al., 1994) . In the adult human brain, Ets2 is expressed in astrocytes of the cortex (Amouyel et al., 1988) . Expression of Ets2 is detected in murine mammary glands and the uterine wall, and becomes highly localized in the alveolar structures of the lungs (Maroulakou et al., 1994) . Humans also express Ets2 during endometrial remodeling (Kilpatrick et al., 1999) and in the ovaries. It remains to be determined whether Ets2 dysfunction is associated with the observed ovarian abnormalities in Down's syndrome (Rowe and Propst, 1992) .
Erg was originally identi®ed in a COLO 320 cDNA library Reddy et al., 1987) . Erg is initially expressed in the blood islands of the yolk sac, mesodermal-and extra-mesodermal tissues, and in embryonic endothelial tissues. Intra-and extra-embryonic endothelial cells expressing Erg include the vascular endothelium and the placental endothelial cells lining the sinusoids (labyrinthine trophoblast cells), respectively. During embryogenesis, Erg is also highly expressed throughout the formation of the vascular tree, including both intraand extra-embryonic endothelia (Table 1) . Subsequently, endothelial expression decreases until Erg expression is restricted to the forming capillaries of the embryo (Vlaeminck-Guillem et al., 2000) . Mesodermal expression of Erg initiates in the branchial arches and extends to the anterior limb bud. During chondrogenesis, the Erg gene is expressed in precartilaginous regions. Additional mesodermal expression of Erg is found in the mesenchymal components of the genital ridge. Later expression in this region extends to the mesenchyme of the kidneys and urogenital tract. The only extramesodermal expression of Erg occurs at E8.5 in migrating neural cells. This expression ceases with settlement and formation of dorsal root ganglia (Vlaeminck-Guillem et al., 2000) .
Fli1 is closely related to Erg (80% homology in human, 96% homology in mouse). Mouse Fli1 was ®rst identi®ed as a site of Friend virus integration (Ben-David et al., 1991) and human Fli1 was originally cloned from a T cell leukemia line (Watson et al., 1992) . The embryonic expression pattern of Fli1 is parallel to that of Erg in both endothelial and mesodermal tissues, including the urogenital tract and precartilaginous regions (Table  1) (Vlaeminck-Guillem et al., 2000) . It is preferentially expressed in hematopoietic lineages and endothelial cells (Melet et al., 1996) . Fli1 expression pattern is also similar to that of Ets1 (Ben-David et al., 1991 ). Both genes display high level and uniform expression patterns within the newly formed mesoderm, and these expression levels fall as the mesoderm matures (Kola et al., 1993) . Fli1 and Ets1 are highly expressed in endothelial cells and megakaryocytes, and both genes are expressed throughout the adult spleen and thymus (Bhat et al., 1987; Kola et al., 1993) .
In the mouse embryo, Fli1 is expressed in a subset of cells within the extra-embryonic yolk sac, most likely the hemangioblasts (Melet et al., 1996) . Early embryonic expression of Fli1 is primarily restricted to mesenchymal cells. High level expression of Fli1 occurs in the newly formed mesoderm and decreases as organogenesis proceeds (Melet et al., 1996) . In addition, high level Fli1 expression occurs in or near migrating neural crest cells. During mid-gestation, Fli1 is expressed in the developing vasculature and in megakaryocyte-like cells of the liver (Melet et al., 1996) . Fli1 plays an essential role in endothelial cells forming the vasculature and megakaryopoiesis at this stage of embryonic development (Hart et al., 2000; Spyropoulos et al., 2000) . In the adult mouse, megakaryocyte-like cells within the spleen express high levels of Fli1, as do the medulla and cortex structures of the thymus (Melet et al., 1996) . Fli1 is also expressed in platelets (Bastian et al., 1999) and at very low, uniform levels in all other cells (Melet et al., 1996) . TEL1 was originally discovered as a rearranged locus in chronic myelomonocytic leukemia (Golub et al., 1994) , and is frequently found to be re-arranged in human leukemias of both myeloid and lymphoid origin, as well as in solid tumors. It is expressed throughout early embryonic development, both in the yolk sac and embryo-proper. During morphogenesis, embryos express TEL1 at high levels in multiple organs including the developing lungs, kidneys and liver (Table 1) (Wang et al., 1997) . High level TEL1 expression is also detected in neural tissues, including the cranial nerve ganglia, the dorsal root ganglia, the ventral region of the caudal neural tube, and the midbrain (Wang et al., 1997) . At mid-gestation, high levels of TEL1 expression exist in the fetal lungs, liver, thymus and abundantly in hematopoietic lineages (Wang et al., 1998) . Adult tissues that express TEL1 include the heart, brain, spleen, lungs, liver, skeletal muscle, kidneys, and testes (Wang et al., 1997) . Most notably, TEL1 is expressed in bone marrow, where it is essential to hematopoiesis (Wang et al., 1997) .
PU.1 was originally cloned from a murine macrophage cDNA expression library and is implicated in Friend virus-induced erythroleukemia (Moreau-Gachelin, 1994; Moreau-Gachelin et al., 1988 . PU.1 expression is restricted to certain lineages and stages during blood cell development (Figure 1 ) (Hromas et al., 1993a) . It is highly expressed in most hematopoietic lineages, with highest levels in the erythroid, monocytic, granulocytic, and B-lymphoid lineages (Chen et al., 1995; Galson et al., 1993; Hromas et al., 1993b; Klemsz et al., 1990; Ray et al., 1992) . PU.1 is expressed during mid-gestation at high levels in the developing liver, in a speckled pattern in tissue surrounding the neural tube and in mesenchymal cells surrounding the spinal cord (Lichanska et al., 1999) . During late stage embryogenesis, PU.1 expression is detected in the fetal bone marrow, liver, and spleen (Table 1) . Hematopoietic cells expressing PU.1 include monocytes, macrophages, neutrophils, mast cells, B cells and early erythroblasts (Anderson et al., 1998a; Galson et al., 1993; Henkel and Brown, 1994; Klemsz et al., 1990) . While no expression of PU.1 is found in the T cells (Ray et al., 1992) , it is expressed at low levels in the murine thymus (Faust et al., 1993; Hromas et al., 1993b; Klemsz et al., 1990) . In adult tissues, PU.1 is highly and speci®cally expressed in lymphoid and hematopoietic tissues, including the spleen, thymus and bone marrow (Fisher and Scott, 1998; Klemsz et al., 1990) . Adult mouse and human hematopoietic cells expressing PU.1 include macrophages, mast cells, dendritic cells, B lymphocytes, proerythroblasts, osteoclasts, and granulocytes (Fisher and Scott, 1998; Tenen et al., 1997) .
Human SpiB was initially cloned from a Burkitt lymphoma cell cDNA library using the Ets domain of PU.1 as a probe. During late-stage embryogenesis in the mouse, SpiB is expressed in the white pulp of the spleen, axillary and mesenteric lymph nodes, and the medullary region of the thymus (Table 1) (Ray et al., 1992) . In adult mice, low level SpiB expression is detected in the medulary-thymocytes, while high levels are detected in splenocytes. The germinal centers of the spleen and the axillary and mesenteric lymph nodes continue to express SpiB throughout adulthood (Su et al., 1996) . Expression of SpiB is restricted to the lymphoid lineages, and is not expressed in myeloid cell lines or peripheral blood neutrophils. Immature B cells demonstrate low level SpiB expression, while immature T cells demonstrate high level expression. In contrast, as these cells mature in the white pulp of the spleen, B cells express high levels, while T cells express much lower levels (Su et al., 1996 (Su et al., , 1997 .
Elf1 was originally cloned from a human T cell cDNA library and found to be associated with B-and T-cell development (Thompson et al., 1991 . Elf1 expression is ®rst detected at very low levels throughout the embryo proper during early embryogenesis. During morphogenesis, high level Elf1 expression is detected in the cortical and medullary regions of the thymus (Table 1) . Elf1 is also expressed in the developing spleen. In addition, it is expressed at high levels in multiple developing epithelial tissues, including the lining of the nose, mouth, lungs, gut, skin, urinary tract and the central nervous system (Bassuk et al., 1998) . Elf1 is primarily expressed in the hematopoietic tissues of adult mice and humans (Bassuk et al., 1998; Davis and Roussel, 1996; Thompson et al., 1992) . Elf1 is expressed in quiescent lymphocytes . In murine tissues, regions of high level expression include the thymus, spleen and bone marrow. Elf1 is also expressed in the kidneys, bladder, testes, liver, small intestine, heart, lungs, ovaries and oviducts. Additionally it plays a unique role in epithelial-speci®c gene expression in the human endometrium during the menstral cycle (Kilpatrick et al., 1999) .
The PEA3 sub-family is composed of three members, including Erm (ETV5) (Chotteau- Lelievre et al., 1997; Monte et al., 1994; Nakae et al., 1995) , Er81 (ETV1) Jeon et al., 1995; Monte et al., 1995) , and PEA3 (E1AF or ETV4) (Friedman et al., 1994; Higashino et al., 1993; Xin et al., 1992) . Each member of the PEA3 sub-family of genes demonstrates unique and overlapping patterns of expression that often re¯ect their function in mesenchymal-epithelial interactions (Chotteau- Lelievre et al., 1997) . They appear to be co-expressed in dierent tissue compartments with speci®c expression in dierent cell types. Expression of PEA3 sub-family members in ectoderm derivatives begins at completion of neural tube closure and continues through late embryonic neurogenesis. In the central nervous system, these genes are expressed in speci®c regions of brain neuroepithelium, the surrounding cephalic mesenchyme, and the¯oor plate of newly formed spinal cord. This expression is maintained in all progressive steps of neural dierentiation. In neural crest derivatives, PEA3 sub-family expression is detected in the branchial arches, cranial ganglia and neurons (Table 1 ). All three PEA3 genes are expressed in the choroid plexus. During organogenesis, the PEA3 sub-family is dierentially expressed in mesenchyme and epithelium in optic, otic, olfactory, and tooth development. At mid-gestation, the developing mammary gland epithelium expresses all three PEA3 genes. The earliest detectable PEA3 sub-family expression in mesodermal derivatives occurs in the myotome and dermotome precursor cells of the myogenic lineage. The PEA3 sub-family is also expressed in the chondrogenic lineages, beginning in the sclerotome precursor cells. Mesodermal expression of the PEA3 sub-family in the developing organs occurs in tissue compartments comprising the heart, kidney, and limbs. Endodermal expression of the PEA3 sub-family is detected in the gut, salivary gland, thymus, thyroid and lungs. The Erm and PEA3 genes are primarily expressed within the developing epithelium, whereas Er81 is primarily con®ned to the surrounding mesenchyme (Chotteau- Lelievre et al., 1997) . In adult human and murine tissues, the PEA3 sub-family members are expressed at dierent levels throughout the skeletal muscles (Chotteau- Lelievre et al., 1997) and sensory and motor neurons (Lin et al., 1998) , with high levels appearing in the brain (Monte et al., 1994 (Monte et al., , 1995 . All three genes are expressed in the colon. High level Erm and Er81 expression has been demonstrated in the kidneys, lungs and heart, while no PEA3 expression is detected in these organs. Erm is the only PEA3 sub-family member expressed in the adult salivary glands (Chotteau- Lelievre et al., 1997) .
Ets transcription factors in Hematopoiesis, Vasculogenesis and Angiogenesis
Ets1 plays an important role in the early stages of organ morphogenesis (Kola et al., 1993) and is later required for the maintenance and survival of mature lymphoid cells (Bories et al., 1995; Muthusamy et al., 1995) . Preferential expression of Ets1 occurs in B, T and NK cells of adult mice, with high levels in the CD3+ subclass of peripheral T cells (Figure 1) (Barton et al., 1998; Bassuk and Leiden, 1997; Bhat et al., 1989; Chen, 1985) . Ets1 is not required for the development of B and T cell lineages, but appears to be essential for their survival and maturation (Bories et al., 1995; Muthusamy et al., 1995) . Ets1 is required for the development of functional NK cells in mice (Barton et al., 1998; Walunas et al., 2000) . Regulation of the Ets1 gene occurs at both the transcriptional and posttranslational levels during T-cell activation (Bhat et al., 1989; Pognonec et al., 1988) . Ets1 is highly expressed in quiescent mature T cells and is critical to the maintenance of T cells in the G0 phase of the cell cycle (Bhat et al., 1990; Bories et al., 1995; Chen, 1985; Muthusamy et al., 1995) . Following T-cell activation, a transcriptionally active form of Ets1 is inactivated (Pognonec et al., 1988; Bhat et al., 1990; Rabault and Ghysdael, 1994) . The absence of Ets1 appears to induce apoptosis in T cells (Bories et al., 1995; Muthusamy et al., 1995) . In B cells, Ets1 appears to be required to block terminal dierentiation to plasma cells. Hence, Ets1 knockout mice display a marked increase in the number of plasma cells (Bories et al., 1995; Muthusamy et al., 1995) . The defects displayed by Ets1 knockout mice suggest that Ets1 is necessary for survival of mature T cells, quiescent B cells (Bories et al., 1995; Muthusamy et al., 1995) , and functional NK and NK T cells (Barton et al., 1998; Walunas et al., 2000) .
In humans, Ets1 is expressed at high levels in proliferating vascular endothelial cells of the developing embryo, and in blood vessels of the adult during angiogenesis (Wernert et al., 1992) . In vitro, Ets1 increases endothelial cell adhesion and stimulates endothelial organization into capillary-like structures (Mattot et al., 2000) . It is notable that human fetal blood vessels display high levels of Ets1 (Kola et al., 1993; Luton et al., 1997) . Ets1 is expressed uniformly in cells of mesodermal origin in both the embryo as well as the maternal decidua, suggesting a role for Ets1 in vascular re-organization. It is notable that Ets1 is co-expressed in the maternal decidua with the target gene, urokinase plasminogen activator, suggesting a role for Ets1 in the transcriptional activation of this protease during vascular re-organization (Grevin et al., 1993; Kola et al., 1993) . Ets1 is expressed in endothelial cells of the forming hypothalamo-hypophyseal blood vessels in the rat brain (Laurent-Huck et al., 1996) . During murine organogenesis, Ets1 is also expressed in angiogenic regions, including the kidneys and liver (Maroulakou et al., 1994) . In situ hybridization analysis demonstrates Ets1 expression in mesenchymal cells of developing organs. Thus, Ets1 plays an important role in mesodermal cells associated with morphogenic processes such as organ formation and tissue remodeling (Kola et al., 1993; Maroulakou et al., 1994) . Despite its expression in embryonic blood vessels, Ets1 is not essential for embryonic vasculogenesis, as evidenced by normal blood vessel development in Ets1 knockout embryos (Bories et al., 1995; Lelievre et al., 2000; Muthusamy et al., 1995) . The overlapping pattern of expression of Ets1, Erg and Fli1 may suggest functional redundancy during embryonic vascular development. Ets1 is highly expressed in proliferating human endothelial cells during tumor Figure 1 Schematic illustration of hematopoietic and endothelial cell development. Expression of Ets transcription family members is documented as follows: (+) low expression, (++) moderate expression, and (+++) high expression. Blue arrows/transcription factors demonstrate requirement for indicated Ets transcription factor in commitment to the next step of cellular dierentiation angiogenesis and re-endothelialization after injury, but not in con¯uent endothelial cells (Wernert et al., 1992) .
Ets2 may play an important role in regulating cellular growth and dierentiation. Ets2 and Ets1 show reciprocal patterns of expression during T cell activation: Ets2 is not expressed in quiescent T cells (where Ets1 is expressed) and is expressed in activated cells (where Ets1 is not expressed) (Figure 1) (Bhat et al., 1987 (Bhat et al., , 1994 . Also, in late stage B-cell maturation, Ets2 expression is markedly increased. In myeloid-lineage dierentiation, Ets2 is induced during the maturation of pro-monocytes to macrophages. In this context, Ets2 appears to be an early-response gene whose activity is linked to cellular proliferation, as demonstrated during macrophage regeneration (Boulukos et al., 1990) . It is also essential for the proliferative response of CSF-1 and contributes to proliferation, primarily in liver regeneration (Bhat et al., 1987; Langer et al., 1992) . However, ES carrying a targeted disruption of Ets2 do not demonstrate defects in their ability to produce functional macrophages . Collectively, these data suggest that Ets2 may play a role in activation or signaling in macrophages (Reddy et al., 1994; Yang et al., 1996) , and is not essential to the myeloid development. Additionally, Ets2 is important for migration and dierentiation of embryonic trophoblast cells to form a hybrid vasculature with the maternal blood from their origin in the ectoplacental cone (Yamamoto et al., 1998) .
Erg is preferentially and strongly expressed in the immature B-and T-lymphoid lineages (Anderson et al., 1999a) . However, as these cells mature, Erg expression is markedly reduced (Figure 1 ). The downregulation of Erg during T-cell dierentiation may be necessary for maturation (Barton et al., 1998) , as is observed for Ets1 in T cell activation (Bhat et al., 1990; Bories et al., 1995; Chen, 1985; Muthusamy et al., 1995) . Expression of Erg during embryonic development of the vascular tree progressively decreases with endothelial maturation. Erg expression is then con®ned to forming capillaries, suggesting it plays a key role in vasculogenesis (Vlaeminck-Guillem et al., 2000) .
Fli1 is essential for the commitment and/or dierentiation of normal hematopoietic lineages (Figure 1 ) (Ben-David et al., 1991; Spyropoulos et al., 2000) . Fli1 is key to the maturation of the megakaryocyte lineage (Hart et al., 2000; Spyropoulos et al., 2000) and potentially important in the lymphoid lineage (Leiden and Thompson, 1994; McCracken et al., 1994) . In T cells, it is moderately expressed throughout dierentiation. Fli1 mutation does not aect T cell numbers or morphology in the peripheral lymphoid organs. It is likely that the gene plays a more speci®c role in the survival and/or proliferation of a prethymic T-cell progenitor (Melet et al., 1996) . In quiescent T cells, it is expressed at high levels, but it is down-regulated with T-cell activation (Anderson et al., 1999b) . In B cells, Fli1 expression increases with maturation/dierentiation into plasma cells. However, over-expression of this gene in transgenic mice results in B cells that are hyperresponsive to mitogenic stimuli and demonstrate marked reduction in apoptosis and prolonged survival in in vitro culture .
Fli1 transgenic animals demonstrate a moderate reduction in erythroid progenitors and signi®cant reduction in early progenitors, CFU-mix and CFU-GM, during the yolk sack stage (Spyropoulos et al., 2000) . Fli1 can trans-activate the GATA-1 gene, which is essential to erythrocyte maturation and is an early marker for embryonic hematopoiesis (Hromas and Klemsz, 1994) . Therefore, Fli1 may assist in the establishment and maintenance of hematopoietic lineages, accounting at least partially for the developmental defects displayed by knockout mice (Spyropoulos et al., 2000) . Additionally, dramatic reduction in embryonic megakaryocyte and megakaryocyte-derived platelet numbers in these knockout mice indicate that Fli1 is essential to megakaryopoiesis (Hart et al., 2000; Spyropoulos et al., 2000) . These hematopoietic abberations may correlate to the hemorrhagic phenotype of Fli1 knockout mice (Spyropoulos et al., 2000) . Overexpression of Fli1 in K562 cells correlates with, and can induce, megakaryocytic dierentiation (Athanasiou et al., 1996) . Also, it is argued that Fli1 is essential for the function of endothelial cells of the decidual blood vessels (Melet et al., 1996) . During mid-gestation embryogenesis, it plays a key role in newly formed endothelial cells involved in vasculogenesis (Hart et al., 2000) . It also is important in the regulation of vascular integrity within the vascular plexus of the cerebral meninges (Hart et al., 2000) . Fli1 is not detectable in adult endothelial cells (Melet et al., 1996) .
TEL1 is dispensable for embryonic hematopoiesis. In TEL1 knockout embryos, erythroid-myeloid lineages proceed normally with commitment and dierentiation (Wang et al., 1997) . However, the absence of TEL1 results in aberrant development of T and B cells, as well as their progenitors (Figure 1) (Wang et al., 1998) . Immediately after birth and in adult mice, TEL1 appears to be essential to hematopoiesis in the bone marrow (Wang et al., 1998) . Knockout of TEL1 in mice results in the inability to re-establish hematopoiesis in the bone marrow after transfer of this function from the embryonic liver. TEL1 is also crucial for the maintenance of hematopoietic stem cells and multipotential progenitors within the bone marrow compartment (Wang et al., 1998) , and may play a role in homing of these cells (Potter et al., 2000) . TEL1 protein has been shown to be both a transcriptional activator and repressor, requiring homo-dimerization/ oligomerization (Lopez et al., 1999) . It also associates with Fli1, inhibiting Fli1 transactivation activity and thereby preventing the activation of target genes (Bassuk and Leiden, 1995; Kwiatkowski et al., 1998) .
TEL1 is implicated in normal structural maintenance of hematopoietic tissues forming the vasculature in the yolk sacs of embryos. Knockout embryos often lack the ability to produce branching vitelline vessels and, by E10.5, cannot maintain the integrity of more complex vascular networks necessary for embryonic development. This defect causes breakdown of yolk sac angiogenesis and leads to embryonic lethality by E12.5. Knockout mice also demonstrate increased apoptosis in neural and mesenchymal tissues, highlighting the importance of this transcription factor in these tissues (Wang et al., 1997) .
PU.1 is a potent regulator of proliferation and dierentiation in the hematopoietic system (Figure 1 ) (Brass et al., 1999) . It does not aect the ability of hematopoietic stem cells to initially commit to either the myeloid or lymphoid lineage (Anderson et al., 1999b; Fisher and Scott, 1998; Henkel et al., 1996 Henkel et al., , 1999 . The absence of PU.1 during embryogenesis results in delayed development and reduced numbers of T cells, likely due to the inecient commitment and/or early dierentiation of T-cell progenitors Spain et al., 1999) . Without PU.1, B cells demonstrate marked abnormalities in their B cell mediated signal transduction (Garrett-Sinha et al., 1999) . Additionally, terminally dierentiated B cells appear to be absent in PU.1 knockout mice . Low levels of PU.1 are required for the maturation of pro-B cells from the multipotential lymphoid progenitor (DeKoter and Singh, 2000) . Moreover, DeKoter and Singh (2000) recently demonstrated that high level expression of PU.1 induces dierentiation of macrophages rather than promoting proliferation of their progenitors, and blocks Blymphocyte development, which requires low levels of PU.1. Indeed, earlier studies have shown that PU.1 is expressed at higher levels in myeloid rather than lymphoid cells (Chen et al., 1995; Henkel and Brown, 1994; Hromas et al., 1993b; Klemsz et al., 1990; Ross et al., 1994) . In the myeloid lineage, PU.1 is more highly expressed during early dierentiation of granulocytes, erythrocytes, and megakaryocytes, but not in mature erythrocutes, granulocytes, endothelial cells, or osteocytes (Hromas et al., 1993b; Lichanska et al., 1999) . Removal of PU.1 in knockout mice results in an inability to produce functional macrophages, though it is not essential for commitment to this lineage (Anderson et al., 1999a; Guerriero et al., 2000; Henkel et al., 1996 Henkel et al., , 1999 . Neutrophils, which normally express PU.1 at later stages of maturation (Hromas et al., 1993b) , are present in PU.1 de®cient animals, but fail to terminally dierentiate and are unresponsive to functional stimuli, including hormones (Anderson et al., 1998b; McKercher et al., 1996) . PU.1 is essential for the development of myeloid-derived, but not lymphoid-derived, dendritic cells (Guerriero et al., 2000) . PU.1 also functions within immature erythroblasts, but is suppressed as these cells dierentiate into erythrocytes (Hromas et al., 1993b) . The continued expression of PU.1 in erythroblasts results in growth immortalization and subsequent conversion to an erythroleukemic state (Fisher and Scott, 1998) . Taken together, the above ®ndings indicate that PU.1 is a key dosage-dependent regulator in the development of speci®c hematopoietic lineages. The necessary role of PU.1 in macrophage development suggests its potential importance in vasculogenesis and angiogenesis via governing the remodeling of tissue.
SpiB is closely related to PU.1 through both sequence homology and function. SpiB expression is restricted to the lymphoid lineages, with high levels in B cells and low levels in T cell progenitors (Figure 1 ) (Chen et al., 1995; Su et al., 1996 Su et al., , 1997 . SpiB expression decreases during T-cell maturation from the multipotential lymphoid progenitor, but increases markedly with B-cells maturation, suggesting that SpiB plays a key role in dierentiation of lymphoid cell types (Su et al., 1996) . Removal of SpiB in knockout mice results in selectively defective T-cell humoral responsiveness and severely¯awed B-cell-mediated responses. Though B cells in these animals can mature, they cannot function. Additionally, spleen sections from these knockout mice demonstrate large numbers of apoptotic B cells, signifying that SpiB may be essential to B-cell survival. These knockout animals also lack the ability to form or maintain normal splenic germinal centers. This evidence suggests that SpiB is required not only for production of functionally viable B cells, but also for the maintenance of these cells (Su et al., 1997) . Myeloid cells do not express signi®cant levels of SpiB, suggesting a limited role in myeloid dierentiation and function (Su et al., 1997) .
Ets transcription factors are implicated in epithelialmesenchymal interactions and morphogenesis
The complex interactions between cells and components of their surrounding extracellular-matrix are critical to epithelial-mesenchymal interactions and strongly in¯uence cell dierentiation, migration and proliferation (Lukashev and Werb, 1998) . Remodeling of the extracellular matrix occurs during embryonic morphogenesis and in physiological and pathological processes such as wound healing (Raghow, 1994; Werb and Chin, 1998) and tumorigenesis (Lukashev and Werb, 1998; Sternlicht et al., 1999) . Several Ets transcription factors are implicated in epithelialmesenchymal and extracellular matrix interactions by their co-incident expression in tissues undergoing morphogenesis and their association with the regulation of metalloproteinase expression. In murine embryos, Ets1 is expressed in mesenchymal cells adjacent to epithelial structures when inductive epithelial-mesenchymal interactions occur, and in association with the degradation and remodeling of the extracellular matrix (Kola et al., 1993) . Ets1 is expressed in the dermis before the formation of epithelial cutanteous structures, limb buds, gut, and during branching morphogenesis in the kidneys and lungs near growing or invading epithelial buds (Chen and Little, 1987; Matrisian and Hogan, 1990) . Signi®cant in mesenchymal remodeling and angiogenesis is Ets1 regulation of genes coding for matrix-degrading metalloproteinases, such as stromelysin and urokinase plasminogen activator, which are necessary for extracellular matrix turnover and tumor invasion (Gomez et al., 1997; Grevin et al., 1993; Thompson et al., 1992; Wernert et al., 1992) . The PEA3 sub-family of transcription factors is similarly involved in morphogenesis via transcriptional regulation of metalloproteinases (Higashino et al., 1995; Matrisian, 1992; Wasylyk et al., 1991) . All three sub-family members are expressed and implicated to function in organs in which epithelialmesenchymal interactions occur (Chotteau- Lelievre et al., 1997) . Ets2 knockout mice are severely growth retarded early in development, resulting in embryonic lethality and resorption by E8.5. These mutant embryos exhibit several defects, including mis-expression of matrix metalloproteinase-9, which is a key molecule in extracellular matrix remodeling. This indicates the potential contribution of Ets2 to epithelial-mesenchymal interactions, its absence resulting in a phenotype exhibiting defects such as failed ectoplacental cone formation (Yamamoto et al., 1998) . Additionally, absence of Ets2 in ®broblasts results in aberrant growth factor signaling and defective metalloproteinase expression within these cells (Yamamoto et al., 1998) . Likewise, Erg is involved in epithelialmesenchymal interactions through the regulation of extracellular matrix proteins, including stromelysin-1 and collagenase-1. However, Ets2 and Erg dierentially regulate collagenase-1 and stromelysin-1 promoter activity: Ets2 activates both promoters, while Erg only induces collagenase-1 (Buttice et al., 1996) . Fli1 is similar to Erg in expression pattern and function involving morphogenetic processes. During mid-gestation, high level expression of Fli1 occurs in the mesenchyme and the cellular layer of the columnar epithelium adjacent to the basement membrane and mesenchyme. This expression possibly correlates with hemorrhagic defects found in the neuroectoderm (columnar epithelium) and extracellular matrix of Fli1 knockout mice (Spyropoulos et al., 2000) . Thus, the normal expression of Fli1 is implicated in the integrity of tissues within the developing murine embryo.
Ets transcription factors in tissue and organ development
Brain and central nervous system Several Ets transcription factors are normally expressed in the developing brain and central nervous system. Ets-1 is expressed in the central nervous system only during the earliest developmental stages (Kola et al., 1993; Maroulakou et al., 1994) . High level expression of Ets1 in these tissues occurs during embryonic vasculogenesis of the central nervous system. Ets1 expression levels are greatly reduced in fully dierentiated tissues, but are maintained in adults undergoing morphogenetic processes and/or blood vessel formations (Kola et al., 1993; Wernert et al., 1992) . Fli1 is also involved in blood vessel formation linked to neural development. In the absence of Fli1, murine embryos display marked aberrations in intra-cranial vascular development during mid-gestation. This appears to be the result of disruption of vascular integrity, possibly occurring due to abatement of cell ± cell adhesion between endothelial cells comprising the meninges (Hart et al., 2000) . Ets-2 is linked to neural development in mice by its expression in the central nervous system during late embryogenesis. Expression is localized in the cerebellum, hippocampus and cerebral cortex and is maintained in adult animals (Kola et al., 1993; Maroulakou et al., 1994) . High levels of Ets2 expression are also detected in post-mitotic neurons (Maroulakou et al., 1994) , suggesting that Ets2 may be necessary for correct neuronal function. Ets2 and Ets1 are expressed in astrocytes from human cortex sections (Amouyel et al., 1988) . Likewise, the expression patterns for PEA3 sub-family members is also the basis for their importance to neural development. Expression of Er81 and PEA3 are coincident in functionally correlated sensory and motor neurons that innervate common muscle targets. Ets expression in these regions is governed by the peripheral target tissue. Therefore, Er81 and PEA3 are potentially important to the development of selective connections between sensory and motor neurons in the developing spinal cord (Lin et al., 1998) . Er81 knockout mice display distinct neuronal defects, most notably within dorsal root ganglia, demonstrating the importance of Er81 in neuronal function (Arber et al., 2000) . Erg is expressed within migrating neural crest cells, and this expression ceases with settlement and formation of dorsal root ganglia (Vlaeminck-Guillem et al., 2000) . The in vivo importance of TEL1 in neurogenic processes is evident in knockout mice. These mice exhibit many speci®c apoptotic neuronal defects, including those within the developing neural tube, dorsal root ganglia, and the cranial nerve ganglia, where high levels of TEL1 expression occur during mid-gestation. Apoptosis, evident in these cell populations, may lead to neural defects at later stages in murine development (Wang et al., 1997) .
Cartilage and bone Expression of several Ets transcription factors is strongly linked to cartilage and bone formation, primarily during development of skeletal structure. Ets2 is highly expressed in embryonic cartilage and bone (Maroulakou et al., 1994) , and is potentially involved in the formation of these tissues. However, this expression does not continue in mature bones after birth (Crepieux et al., 1994; Maroulakou et al., 1994) . The overexpression of Ets2 in transgenic mice results in skeletal abnormalities similar to those displayed in trisomy-16 mice and Down's syndrome (Sumarsono et al., 1996) . Ets2 expression aects the in vitro dierentiation of osteoblasts. By contrast, Ets1 is expressed during proliferation of osteoblast cells (Vary et al., 2000) . Similar to Ets1, Erg is expressed in sclerotomal cells, which later form the cartilaginous skeleton (Dhordain et al., 1995; Grevin et al., 1993) . However, Ets1 is down-regulated in chondroblasts, while Erg and PEA3 continue to be expressed in the cartilage (Dhordain et al., 1995; Ganan et al., 1996) . Erg is potentially important in the regulation of skeletal development, and is highly expressed in pre-cartilaginous condensation zones and in the skeletal primordia during embryogenesis (Vlaeminck-Guillem et al., 2000) . Erg transcripts are also detectable in dierentiating chondroblast cells during cartilage deposition (Dhordain et al., 1995) . PEA3 sub-family genes expression, similar to Ets1 and Erg, are detected in murine sclerotomal cells that form the vertebral axis and ribs, and in the appendicular skeleton. PEA3 is also expressed in chondroblasts, as well as in perichondrial cells lining newly formed cartilage (Chotteau- Lelievre et al., 1997) . The PU.1 transcription factor is implicated in osteoclast formation. The absence of this gene in mice inhibits the proper formation of osteoclasts in vivo, resulting in osteopetrosis (Tondravi et al., 1997) .
Mammary gland Several Ets transcription factors are highly expressed in mammary gland tissue during normal development. Additionally, aberrant expression of these genes is linked to tumorigenic processes in mice and humans. Ets1 expression in the mammary gland is ®rst detected in the mesenchymal compartment at the beginning of primary epithelial bud formation. At later developmental stages, Ets1 is detected in the invading extremities of epithelial ducts. Ets1 expression correlates with invasive processes in tumor development including angiogenesis and stromal cell proliferation (Delannoy-Courdent et al., 1998) . Ets1 is also coexpressed with plasminogen (uPA) in human mammary epithelial cultures during tubulogenesis in normal cells and invasion by cancerous cells. uPA is a target for activation by Ets1 in these cells, inducing a cascade of proteolytic events that degradate the extracellular matrix and promote tumor metastasis (DelannoyCourdent et al., 1996) . PEA3 also plays a role in mammary epithelial development, migration and invasion (Chotteau- Lelievre et al., 1997; Kaya et al., 1996) . All three PEA3 sub-family members are highly expressed in the epithelial bud at the onset of mammary gland development in the embryo. Expression of the PEA3 sub-family also occurs during tubular morphogenesis in mammary development (Chotteau- Lelievre et al., 1997) . In addition to mammary gland development, PEA3 is associated with breast cancer in the mouse (Chotteau- Lelievre et al., 1997; Trimble et al., 1993) and human (Baert et al., 1997; Xing et al., 2000) . The PEA3 sub-family of transcription factors play a potential role in the regulation of growth and progression of human breast cancer (Xing et al., 2000) . Several oncogenic pathways, including activated ErbB2/neu, Src, Ras, and Raf, activate Ets2 transcription in mammalian cells (Jousset et al., 1997; McCarthy et al., 1997; Yang et al., 1996) . Ets2 appears to be a transformation-mediator in mammary epithelium because dominant-negative mutant constructs of Ets2 can block transformation by Neu/Ras (Galang et al., 1996) . Ets2 dominant negative mutants abolish anchorage-dependent growth and CSF1-stimulated invasion by breast cancer cells (Sapi et al., 1998) . Moreover, targeting of the Ets2 allele causes inhibition of mammary gland tumor progression in female mice carrying the polyoma virus middle T oncogene (Neznanov et al., 1999) . In addition, Ets2 functionally correlates with regulation of steroid hormones related to breast cancer. For example, Conrad et al. (1994) demonstrate that Ets2 protein can impair activation of the pituitary prolactin gene.
Concluding remarks
Ets transcription factors are critical regulators of fundamental developmental processes. Study of Ets expression in normal and genetically manipulated mice has revealed unique and essential roles for many of these transcription factors in hematopoiesis, as well as organ development. Additionally, over-expression of Ets genes has been correlated with a number of human neoplasias. This wide range of eects raises the issue of identifying Ets target genes involved in common molecular mechanisms that govern underlying developmental processes. Ets proteins have been shown to interact with a number of extracellular, cell-surface and intracellular proteins involved in tissue and cellular morphogenesis and remodeling. Therefore, it is necessary to identify additional targets in the Ets network of functions. Our understanding of the roles of the Ets family of transcription factors will require more mammalian models based on a network of Ets genes and their targets, rather than on a single gene in a pathway. Such studies will allow further insights into the inter-relation between family member function and redundancy. The development of new mouse models will also provide useful tools for better understanding the clinical importance of the Ets transcription factor family.
